User profiles for C. Dario Vizza
 | Carmine Dario VizzaUniversity of Rome La Sapienza Verified email at uniroma1.it Cited by 14677 |
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry
Background Originally reported to occur predominantly in younger women, idiopathic pulmonary
arterial hypertension (IPAH) is increasingly diagnosed in elderly patients. We aimed to …
arterial hypertension (IPAH) is increasingly diagnosed in elderly patients. We aimed to …
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary …
Background— For almost 30 years, anticoagulation has been recommended for patients with
idiopathic pulmonary arterial hypertension (IPAH). Supporting evidence, however, is limited…
idiopathic pulmonary arterial hypertension (IPAH). Supporting evidence, however, is limited…
Pregnancy outcomes in pulmonary arterial hypertension in the modern management era
…, A Torbicki, A Peacock, CD Vizza… - European …, 2012 - Eur Respiratory Soc
Previous studies have reported mortality rates of up to 56% associated with pregnancy in
pulmonary arterial hypertension (PAH) but the management of this disease has changed …
pulmonary arterial hypertension (PAH) but the management of this disease has changed …
[HTML][HTML] Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias
MM Hoeper, J Behr, M Held, E Grunig, CD Vizza… - PloS one, 2015 - journals.plos.org
… Carmine Dario Vizza has received fees for serving as a speaker, consultant and an advisory
board member, from the following companies: Actelion, Dompè, GSK, Italfarmaco, Lilly, …
board member, from the following companies: Actelion, Dompè, GSK, Italfarmaco, Lilly, …
Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis
Objectives Pulmonary arterial hypertension (PAH) occurs in various connective tissue diseases
(CTDs). We sought to assess contemporary treatment patterns and survival of patients …
(CTDs). We sought to assess contemporary treatment patterns and survival of patients …
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification
strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-…
strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-…
Right and left ventricular dysfunction in patients with severe pulmonary disease
CD Vizza, JP Lynch, LL Ochoa, G Richardson… - Chest, 1998 - Elsevier
Objective To determine the prevalence of right and left ventricular dysfunction in a prescreened
population of patients with severe pulmonary disease, and to analyze the relationship …
population of patients with severe pulmonary disease, and to analyze the relationship …
[HTML][HTML] COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
Background Risk stratification plays an essential role in the management of patients with
pulmonary arterial hypertension (PAH). The current European guidelines propose a three-…
pulmonary arterial hypertension (PAH). The current European guidelines propose a three-…
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre …
Background Riociguat and phosphodiesterase-5 inhibitors (PDE5i), approved for the
treatment of pulmonary arterial hypertension (PAH), act on the same pathway via different …
treatment of pulmonary arterial hypertension (PAH), act on the same pathway via different …
[HTML][HTML] Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
… C. Dario Vizza has received fees from Actelion, Bayer, GSK, MSD, Pfizer, and United
Therapeutics Europe. Anton Vonk-Noordegraaf has received fees for lectures and/or consultation …
Therapeutics Europe. Anton Vonk-Noordegraaf has received fees for lectures and/or consultation …